JP2005508368A - 高コレステロール濃度に関連した疾患の治療方法 - Google Patents

高コレステロール濃度に関連した疾患の治療方法 Download PDF

Info

Publication number
JP2005508368A
JP2005508368A JP2003541772A JP2003541772A JP2005508368A JP 2005508368 A JP2005508368 A JP 2005508368A JP 2003541772 A JP2003541772 A JP 2003541772A JP 2003541772 A JP2003541772 A JP 2003541772A JP 2005508368 A JP2005508368 A JP 2005508368A
Authority
JP
Japan
Prior art keywords
composition
compound
alkyl
hydrogen
hydroxy
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2003541772A
Other languages
English (en)
Japanese (ja)
Other versions
JP2005508368A5 (https=
Inventor
リャオ、シュツン
ソン、チン
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
University of Chicago
Original Assignee
University of Chicago
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by University of Chicago filed Critical University of Chicago
Publication of JP2005508368A publication Critical patent/JP2005508368A/ja
Publication of JP2005508368A5 publication Critical patent/JP2005508368A5/ja
Pending legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07J—STEROIDS
    • C07J9/00—Normal steroids containing carbon, hydrogen, halogen or oxygen substituted in position 17 beta by a chain of more than two carbon atoms, e.g. cholane, cholestane, coprostane
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/575—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of three or more carbon atoms, e.g. cholane, cholestane, ergosterol, sitosterol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07J—STEROIDS
    • C07J41/00—Normal steroids containing one or more nitrogen atoms not belonging to a hetero ring
    • C07J41/0033—Normal steroids containing one or more nitrogen atoms not belonging to a hetero ring not covered by C07J41/0005
    • C07J41/0055—Normal steroids containing one or more nitrogen atoms not belonging to a hetero ring not covered by C07J41/0005 the 17-beta position being substituted by an uninterrupted chain of at least three carbon atoms which may or may not be branched, e.g. cholane or cholestane derivatives, optionally cyclised, e.g. 17-beta-phenyl or 17-beta-furyl derivatives
    • C07J41/0061—Normal steroids containing one or more nitrogen atoms not belonging to a hetero ring not covered by C07J41/0005 the 17-beta position being substituted by an uninterrupted chain of at least three carbon atoms which may or may not be branched, e.g. cholane or cholestane derivatives, optionally cyclised, e.g. 17-beta-phenyl or 17-beta-furyl derivatives one of the carbon atoms being part of an amide group

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Engineering & Computer Science (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Cardiology (AREA)
  • Epidemiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Vascular Medicine (AREA)
  • Obesity (AREA)
  • Hospice & Palliative Care (AREA)
  • Hematology (AREA)
  • Diabetes (AREA)
  • Psychiatry (AREA)
  • Urology & Nephrology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Steroid Compounds (AREA)
JP2003541772A 2001-11-08 2002-11-08 高コレステロール濃度に関連した疾患の治療方法 Pending JP2005508368A (ja)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US34802001P 2001-11-08 2001-11-08
PCT/US2002/035900 WO2003039480A2 (en) 2001-11-08 2002-11-08 Method of treating disorder related to high cholesterol concentration

Publications (2)

Publication Number Publication Date
JP2005508368A true JP2005508368A (ja) 2005-03-31
JP2005508368A5 JP2005508368A5 (https=) 2006-01-12

Family

ID=23366328

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2003541772A Pending JP2005508368A (ja) 2001-11-08 2002-11-08 高コレステロール濃度に関連した疾患の治療方法

Country Status (5)

Country Link
EP (1) EP1450816A4 (https=)
JP (1) JP2005508368A (https=)
CA (1) CA2466033A1 (https=)
TW (1) TW200300078A (https=)
WO (1) WO2003039480A2 (https=)

Cited By (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2014526469A (ja) * 2011-09-08 2014-10-06 セージ セラピューティクス， インコーポレイテッド 神経刺激性のステロイド、組成物、およびそれらの使用
WO2015034010A1 (ja) * 2013-09-04 2015-03-12 学校法人常翔学園 核内受容体肝臓ｘ受容体アゴニスト
JP2016514967A (ja) * 2013-03-13 2016-05-26 セージ セラピューティクス， インコーポレイテッド 神経刺激性ステロイド、組成物およびそれらの使用
US10201550B2 (en) 2015-07-06 2019-02-12 Sage Therapeutics, Inc. Oxysterols and methods of use thereof
US10227375B2 (en) 2013-03-13 2019-03-12 Sage Therapeutics, Inc. Neuroactive steroids and methods of use thereof
US10259840B2 (en) 2014-06-18 2019-04-16 Sage Therapeutics, Inc. Oxysterols and methods of use thereof
US10696712B2 (en) 2015-07-06 2020-06-30 Sage Therapeutics, Inc. Oxysterols and methods of use thereof
US10752653B2 (en) 2016-05-06 2020-08-25 Sage Therapeutics, Inc. Oxysterols and methods of use thereof
US10781231B2 (en) 2016-07-07 2020-09-22 Sage Therapeutics, Inc. Oxysterols and methods of use thereof
US11111266B2 (en) 2016-10-18 2021-09-07 Sage Therapeutics, Inc. Oxysterols and methods of use thereof
US11117924B2 (en) 2015-07-06 2021-09-14 Sage Therapeutics, Inc. Oxysterols and methods of use thereof
US11149056B2 (en) 2016-09-30 2021-10-19 Sage Therapeutics, Inc. C7 substituted oxysterols and methods of use thereof
US11149054B2 (en) 2016-10-18 2021-10-19 Sage Therapeutics, Inc. Oxysterols and methods of use thereof
US11884697B2 (en) 2016-04-01 2024-01-30 Sage Therapeutics, Inc. Oxysterols and methods of use thereof

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7078396B2 (en) 2001-05-03 2006-07-18 Arch Development Corporation Method of treating disorder related to high cholesterol concentration
US8399441B2 (en) 2004-10-25 2013-03-19 Virginia Commonwealth University Nuclear sulfated oxysterol, potent regulator of lipid homeostasis, for therapy of hypercholesterolemia, hypertriglycerides, fatty liver diseases, and atherosclerosis
WO2006047022A1 (en) 2004-10-25 2006-05-04 Virginia Commonwealth University Nuclear sulfated oxysterol, potent regulator of cholesterol homeostasis, for therapy of hypercholesterolemia, hyperlipidemia, and atherosclerosis
TW200619191A (en) 2004-10-27 2006-06-16 Sankyo Co Phenyl compounds with more than 2 substitutes
AU2007323998B2 (en) 2006-11-13 2011-09-22 Novartis Ag Substituted pyrazole and triazole compounds as KSP inhibitors
EP2459581A4 (en) 2009-07-29 2012-12-26 Univ Chicago LIVER X-RECEPTOR AGONISTS
US9034859B2 (en) 2011-04-06 2015-05-19 Virginia Commonwealth University Sulfated oxysterol and oxysterol sulfation by hydroxysterol sulfotransferase promote lipid homeostasis and liver proliferation
PL3639828T3 (pl) 2013-12-24 2022-05-02 Virginia Commonwealth University Zastosowanie utlenowanych siarczanów cholesterolu (ocs) w leczeniu ostrej niewydolności wątroby
EP3494125B1 (en) 2016-08-02 2022-06-22 Virginia Commonwealth University Compositions comprising 5-cholesten-3, 25-diol, 3-sulfate (25hc3s) or pharmaceutically acceptable salt thereof and at least one cyclic oligosaccharide
GB201812382D0 (en) 2018-07-30 2018-09-12 Nzp Uk Ltd Compounds

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4217288A (en) * 1977-03-24 1980-08-12 Wisconsin Alumni Research Foundation Anti-vitamin D compounds
JPS61254599A (ja) * 1985-05-07 1986-11-12 Sumitomo Pharmaceut Co Ltd コレステロ−ルのフツ素誘導体
WO2000066611A1 (en) * 1999-04-30 2000-11-09 Arch Development Corporation Steroid derivatives
JP4309661B2 (ja) * 2001-05-03 2009-08-05 ザ ユニバーシティー オブ シカゴ 肝臓ｘ受容体

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS4976857A (https=) * 1972-12-06 1974-07-24
US3963765A (en) * 1973-04-01 1976-06-15 Yehuda Mazur Preparation of derivatives of cholesterol
IL105050A0 (en) * 1992-03-27 1993-07-08 Lilly Co Eli Steroid derivatives
IT1255241B (it) * 1992-07-22 1995-10-20 Simos Contos Derivato di acido biliare e suo uso in terapia

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4217288A (en) * 1977-03-24 1980-08-12 Wisconsin Alumni Research Foundation Anti-vitamin D compounds
JPS61254599A (ja) * 1985-05-07 1986-11-12 Sumitomo Pharmaceut Co Ltd コレステロ−ルのフツ素誘導体
WO2000066611A1 (en) * 1999-04-30 2000-11-09 Arch Development Corporation Steroid derivatives
JP4309661B2 (ja) * 2001-05-03 2009-08-05 ザ ユニバーシティー オブ シカゴ 肝臓ｘ受容体

Non-Patent Citations (4)

* Cited by examiner, † Cited by third party
Title
J.AM.CHEM.SOC., vol. 106, JPN6008066356, 1984, pages 3344 - 3353, ISSN: 0001392207 *
PROC.NATL.ACAD.SCI.USA, vol. 96, JPN6008066354, 1999, pages 266 - 271, ISSN: 0001392208 *
SONG, C. ET AL.: "Selective activation of liver X receptor alpha by 6α-hydroxy bile acids and analogs", STEROIDS, vol. Volume 65, Issue 8, JPN6009040558, August 2001 (2001-08-01), pages 423 - 427, ISSN: 0001392209 *
SONG,C. ET AL: "Hypolipidemic effects of selective liver X receptor alpha agonists", STEROIDS, vol. 66, no. 9, JPN6009040560, September 2001 (2001-09-01), pages 673 - 681, XP004304415, ISSN: 0001392206, DOI: 10.1016/S0039-128X(01)00132-5 *

Cited By (31)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US10759828B2 (en) 2011-09-08 2020-09-01 Sage Therapeutics, Inc. Neuroactive steroids, compositions, and uses thereof
US12129275B2 (en) 2011-09-08 2024-10-29 Sage Therapeutics, Inc. Neuroactive steroids, compositions, and uses thereof
JP2014526469A (ja) * 2011-09-08 2014-10-06 セージ セラピューティクス， インコーポレイテッド 神経刺激性のステロイド、組成物、およびそれらの使用
JP2018021059A (ja) * 2011-09-08 2018-02-08 セージ セラピューティクス， インコーポレイテッド 神経刺激性のステロイド、組成物、およびそれらの使用
US11104701B2 (en) 2013-03-13 2021-08-31 Sage Therapeutics, Inc. Neuroactive steroids and methods of use thereof
JP2016514967A (ja) * 2013-03-13 2016-05-26 セージ セラピューティクス， インコーポレイテッド 神経刺激性ステロイド、組成物およびそれらの使用
JP2020062050A (ja) * 2013-03-13 2020-04-23 セージ セラピューティクス， インコーポレイテッド 神経刺激性ステロイド、組成物およびそれらの使用
JP7579639B2 (ja) 2013-03-13 2024-11-08 セージ セラピューティクス， インコーポレイテッド 神経刺激性ステロイド、組成物およびそれらの使用
US11905309B2 (en) 2013-03-13 2024-02-20 Sage Therapeutics, Inc. Neuroactive steroids and methods of use thereof
US10227375B2 (en) 2013-03-13 2019-03-12 Sage Therapeutics, Inc. Neuroactive steroids and methods of use thereof
JP2022044802A (ja) * 2013-03-13 2022-03-17 セージ セラピューティクス， インコーポレイテッド 神経刺激性ステロイド、組成物およびそれらの使用
WO2015034010A1 (ja) * 2013-09-04 2015-03-12 学校法人常翔学園 核内受容体肝臓ｘ受容体アゴニスト
US10259840B2 (en) 2014-06-18 2019-04-16 Sage Therapeutics, Inc. Oxysterols and methods of use thereof
US10723758B2 (en) 2014-06-18 2020-07-28 Sage Therapeutics, Inc. Oxysterols and methods of use thereof
US11732000B2 (en) 2015-07-06 2023-08-22 Sage Therapeutics, Inc. Oxysterols and methods of use thereof
US10765685B2 (en) 2015-07-06 2020-09-08 Sage Therapeutics, Inc. Oxysterols and methods of use thereof
US11117924B2 (en) 2015-07-06 2021-09-14 Sage Therapeutics, Inc. Oxysterols and methods of use thereof
US10696712B2 (en) 2015-07-06 2020-06-30 Sage Therapeutics, Inc. Oxysterols and methods of use thereof
US10201550B2 (en) 2015-07-06 2019-02-12 Sage Therapeutics, Inc. Oxysterols and methods of use thereof
US11884697B2 (en) 2016-04-01 2024-01-30 Sage Therapeutics, Inc. Oxysterols and methods of use thereof
US10752653B2 (en) 2016-05-06 2020-08-25 Sage Therapeutics, Inc. Oxysterols and methods of use thereof
US11407782B2 (en) 2016-05-06 2022-08-09 Sage Therapeutics, Inc. Oxysterols and methods of use thereof
US10781231B2 (en) 2016-07-07 2020-09-22 Sage Therapeutics, Inc. Oxysterols and methods of use thereof
US11279730B2 (en) 2016-07-07 2022-03-22 Sage Therapeutics, Inc. Oxysterols and methods of use thereof
US11926646B2 (en) 2016-09-30 2024-03-12 Sage Therapeutics, Inc. C7 substituted oxysterols and methods of use thereof
US11149056B2 (en) 2016-09-30 2021-10-19 Sage Therapeutics, Inc. C7 substituted oxysterols and methods of use thereof
US11613556B2 (en) 2016-10-18 2023-03-28 Sage Therapeutics, Inc. Oxysterols and methods of use thereof
US11851457B2 (en) 2016-10-18 2023-12-26 Sage Therapeutics Oxysterols and methods of use thereof
US11111266B2 (en) 2016-10-18 2021-09-07 Sage Therapeutics, Inc. Oxysterols and methods of use thereof
US11149054B2 (en) 2016-10-18 2021-10-19 Sage Therapeutics, Inc. Oxysterols and methods of use thereof
US12180247B2 (en) 2016-10-18 2024-12-31 Sage Therapeutics, Inc. Oxysterols and methods of use thereof

Also Published As

Publication number Publication date
WO2003039480A3 (en) 2003-06-19
EP1450816A4 (en) 2008-02-13
TW200300078A (en) 2003-05-16
CA2466033A1 (en) 2003-05-15
EP1450816A2 (en) 2004-09-01
WO2003039480A2 (en) 2003-05-15

Similar Documents

Publication Publication Date Title
JP2005508368A (ja) 高コレステロール濃度に関連した疾患の治療方法
US20110160174A1 (en) Method Of Treating Disorder Related To High Cholesterol Concentration
JP4309661B2 (ja) 肝臓ｘ受容体
US20040014734A1 (en) Farnesoid X-activated receptor agonists
US8829213B2 (en) Liver X receptor agonists
US20240261282A1 (en) Pharmaceutical compositions and combinations comprising inhibitors of the androgen receptor and uses thereof
EP2709631B9 (en) Antagonists of cb1 receptor
US7078396B2 (en) Method of treating disorder related to high cholesterol concentration
US20060051406A1 (en) Formulation of insoluble small molecule therapeutics in lipid-based carriers
JP2021510372A (ja) 脱髄疾患の治療
WO2012027727A2 (en) Lipomacrocycles and uses thereof
JP2002518514A (ja) テストステロン誘導体
US8246984B2 (en) Formulation of insoluble small molecule therapeutics in lipid-based carriers
JPH01197438A (ja) 更年期障害およびホルモン依存性腫瘍の治療用ならびに避妊薬として使用するための医薬調剤およびその製法
AU2002356919B2 (en) Method of treating disorder related to high cholesterol concentration
CN101193622A (zh) 治疗炎性疾病的方法和组合物
AU2002356919A1 (en) Method of treating disorder related to high cholesterol concentration
CA3215182A1 (en) Pharmaceutical compositions comprising inhibitors of the androgen receptor and uses thereof
TW202140004A (zh) 用於治療ｎａｆｌｄ／ｎａｓｈ及相關疾病之組合
JP2019511486A (ja) 選択的プロゲステロン受容体モジュレーター（ＳＰＲＭ）のプロドラッグ（１１β，１７β）−１７−ヒドロキシ−１１−［４−（メチルスルホニル）フェニル］−１７−（ペンタフルオロエチル）エストラ−４，９−ジエン−３−オン
WO2025140618A1 (zh) 一种用于递送核酸的脂质纳米颗粒及其制备方法和用途
CN108218946A (zh) 一种去氧胆酸类化合物、其制备方法及应用
JPH06234643A (ja) ステロイド外用剤

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20051107

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20051107

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20090811

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20100406